Drug Trial Radar · NCT06473259
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
Last checked: Nov 20, 2026Latest source record: Jun 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Dec 16, 2016
Primary completion
Dec 2026
Study completion Dec 2028
Sponsor
- Lead sponsor
- Santa Chiara HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 25, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Male only
Summary
As written by the sponsor on the registry.
The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice
Conditions
- Prostate Cancer
- Hormone Sensitive Prostate Cancer
- Metastatic Tumor
Interventions
DocetaxelDrug
6 courses of docetaxel 75 mg/sqm iv
Apalutamide Oral TabletDrug
240 mg /daily orally
Enzalutamide Oral TabletDrug
600 mg /daily orally
Abiraterone acetate tabletsDrug
1000 mg /daily orally
Darolutamide Oral TabletDrug
600 mg/daily orally
radiotherapyRadiation
radical radiotherapy on primary tumor
TriptorelinDrug
3,75 mg im/4 w
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression free survivalTime frame: From date of treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Istituto Oncologico Veneto
Padova, Italy · Recruiting
Santa Chiara Hospital
Trento, Italy · Recruiting
Azienda Ospedaliera San Luigi
Orbassano, Torino, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.